INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS-Reference-Cited by-同舟云学术

INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

Published:2017-06 Issue: Volume:35 Page:24-25
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Morschhauser F.¹,Salles G.²,McKay P.³,Tilly H.⁴,Schmitt A.⁵,Gerecitano J.⁶,Johnson P.⁷,Le Gouill S.⁸,Dickinson M.J.⁹,Fruchart C.¹⁰,Lamy T.¹¹,Chaidos A.¹²,Jurczak W.¹³,Opat S.¹⁴,Radford J.¹⁵,Zinzani P.L.¹⁶,Assouline S.¹⁷,Cartron G.¹⁸,Clawson A.¹⁹,Picazio N.²⁰,Ribich S.²¹,Blakemore S.J.²²,Larus J.²³,Miao H.²⁴,Ho P.T.²⁴,Ribrag V.²⁵

Affiliation:

1. Department of Hematology; Centre Hospitalier Universitaire; Lille France

2. Hematology; Lyon-Sud Hospital Center; Pierre-Bénite France

3. Haematology; North Glasgow University Hospitals; Glasgow UK

4. Hematology; Centre de lutte Contre le Cancer Henri Becquerel; Rouen France

5. Hematology; Institut Bergonié; Bordeaux France

6. Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA

7. Medical Oncology; Southampton General Hospital; Southampton UK

8. Service d'Hématologie Clinique; Universite De Nantes; Nantes France

9. Department of Haematology; Peter MacCallum Cancer Centre; Melbourne Australia

10. Hematologie; Centre François Baclesse; Caen France

11. Service d'Hématologie Clinique; CHU de Rennes; Rennes France